Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
Non-Hodgkin Lymphoma
Federal Court Orders EPA to Reexamine Whether Roundup Causes Cancer
In its ruling, the court challenged the Trump-era finding that glyphosate was not a serious health risk and “not likely” to cause cancer.
Disparity in Access to CAR-T Therapy Associated With Lower Income Neighborhoods
Researchers sought to determine the reasons for a disparity in patients who receive CAR-T therapy.
Response to CAR T-Cell Therapy Similar for Minority Patients
Progression-free and overall survival is similar for minority and nonminority patients receiving CAR T-cell therapy for non-Hodgkin lymphoma.
Vaccine-Induced Responses to Omicron, Delta Impaired in Non-Hodgkin Lymphoma Patients
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
Yescarta Approved for Second-Line Treatment of Large B-Cell Lymphoma
The approval was based on data from the phase 3 ZUMA-7 trial.
Bone Marrow Infiltration a Risk Factor for Infusion-Related Reactions in B-Cell NHL
Bone marrow infiltration of lymphoma cells is a risk factor for grade 2 or higher infusion-related reactions in B-NHL treated with rituximab.
Central Nervous System Relapse of Lymphoma Is Not Impacted by Prophylaxis Method
Researchers sought to determine whether the route of administration for prophylaxis would impact CNS relapse in patients with aggressive B-cell non-Hodgkin lymphomas.
Yescarta Labeling Updated to Include Prophylactic Corticosteroid Use
The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.
Risk for Cancer Increased After VTE for Patients With Psoriasis
The absolute risk for overall cancer was 4.7% during the first year of follow-up.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...